While RLR ligands are not yet approved by the Food and Drug Administration (FDA) as a treatment for cancers, accumulating evidence strongly suggests that triggering MDA5 or RIG-I would provide a promising approach for cancer immunotherapy. The gene discussed is DHX58; the disease is cancer.